Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CHOP ± R-HAD induction followed by rituximab ± lenalidomide maintenance in older mantle cell lymphoma
2012-002542-20Phase 3Completed
- Sponsor
- LYSARC
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of lenalidomide in mantle cell lymphoma (MCL) (4 arms), sponsored by LYSARC. Primary endpoint: Progression-free survival. Started Apr 2013; status: completed.
02
Drugs
lenalidomide
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2012-002542-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002542-20.